CYP19A1 and depressive disorder: Participants reported being interested or very interested when asked for interest in any of the IM modalities to address specific symptoms: joint paints due to aromatase inhibitors (Black 71.6% vs. White 66.2%), back pain or other pain (Black 71.0% vs. White 65.9%), fatigue (Black 63.8% vs. White 64.0%), anxiety or stress reduction (Black 61.3% vs. White 63.25), depression or mood changes (Black 50.4% vs. White 52.5%), hot flashes (Black 49.2% vs. White 44.1%), chemotherapy-induced neuropathy (Black 43.2% vs. White 38.0%), and nausea (Black 32.0% vs. White 30.2%).